BioLegend, New York Genome Center Enter into License and Research Agreement for CITE-seq

BioLegend and the New York Genome Center (NYGC) have entered into an exclusive worldwide license and collaborative research agreement for CITE-seq technology for use in the research field. CITE-seq, Cellular Indexing of Transcriptomes and Epitopes by sequencing, developed in the NYGC’s Technology Innovation Lab by a team led by Dr. Marlon Stoeckius, complements BioLegend’s portfolio of antibodies and biomedical reagents. The new CITE-seq technology enables scientists to simultaneously measure protein and RNA expression at the single-cell level, allowing researchers to distinguish different cell types and cell states, and study disease mechanisms at the level of individual cells.

The partnership with the NYGC expands the reach of BioLegend’s antibody and protein portfolio of reagents into the rapidly advancing space of genomic and transcriptomic profiling. In an effort to facilitate standardization of the technology and allow comparison of data across many studies, BioLegend and the NYGC have established a large set of static barcodes, each of which are assigned to unique antibodies/proteins. In advance of the official release of CITE-seq catalog products, and related products for sample multiplexing and doublet identification, BioLegend is now providing specific custom CITE-seq antibody conjugates to interested customers. Whether provided by catalog or in custom form, BioLegend’s oligo-barcoded CITE-seq antibodies establish high-quality reagent standards for this new profiling technology.

“We are very excited about Dr. Stoeckius’ innovative technology, and its applicability to BioLegend’s portfolio of reagents for profiling protein expression in single cells. This approach will surely revolutionize basic and biomedical research. Along with other advancing technologies in this space, giving scientists easy access to quality reagents such as these will significantly accelerate scientific research,” said Gene Lay, BioLegend’s CEO.

  • <<
  • >>